The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB).
Alzheimer's Disease Neuroimaging Initiative
Alzheimer's disease clinical trials
biomarkers
neuroimaging
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
29 Sep 2023
29 Sep 2023
Historique:
revised:
24
08
2023
received:
16
06
2023
accepted:
27
08
2023
medline:
29
9
2023
pubmed:
29
9
2023
entrez:
29
9
2023
Statut:
aheadofprint
Résumé
The Alzheimer's Disease Neuroimaging Initiative (ADNI) Private Partners Scientific Board (PPSB) encompasses members from industry, biotechnology, diagnostic, and non-profit organizations that have until recently been managed by the Foundation for the National Institutes of Health (FNIH) and provided financial and scientific support to ADNI programs. In this article, we review some of the major activities undertaken by the PPSB, focusing on those supporting the most recently completed National Institute on Aging grant, ADNI3, and the impact it has had on streamlining biomarker discovery and validation in Alzheimer's disease. We also provide a perspective on the gaps that may be filled with future PPSB activities as part of ADNI4 and beyond. HIGHLIGHTS: The Private Partners Scientific board (PPSB) continues to play a key role in enabling several Alzheimer's Disease Neuroimaging Initiative (ADNI) activities. PPSB working groups have led landscape assessments to provide valuable feedback on new technologies, platforms, and methods that may be taken up by ADNI in current or future iterations.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States
Organisme : NIBIB NIH HHS
Pays : United States
Organisme : NIH HHS
ID : U01 AG024904
Pays : United States
Informations de copyright
© 2023 AbbVie Inc. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Alzheimer's Disease Neuroimaging Initiative. About Alzheimer's disease neuroimaging initiative (ADNI). Accessed on 2017. https://AdniLoniUscEdu/about/#gov-Container n.d
Liu E, Luthman J, Cedarbaum JM, et al. Perspective: the Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB). Alzheimer's Dement. 2015;11:840-849. doi:10.1016/j.jalz.2015.04.001
Schmidt ME, Siemers E, Snyder PJ, Potter WZ, Cole P, Soares H. The Alzheimer's disease neuroimaging initiative: perspectives of the industry scientific advisory board. Alzheimer's Dement. 2010;6:286-290. doi:10.1016/j.jalz.2010.03.010
Smith T, Gildeh N, Holmes C. The montreal cognitive assessment: validity and utility in a memory clinic setting. Can J Psychiatry. 2007;52:329-332.
Bean J. Rey auditory verbal learning test. encycl. Clin Neuropsychol. 2011:2174-2175.
Kueper JK, Speechley M, Montero-odasso M. The Alzheimer ’ s disease assessment scale - cognitive subscale (ADAS-Cog): modifications and responsiveness in pre-dementia populations . A narrative review. J Alzheimer's Dis. 2018;63:423-444. doi:10.3233/JAD-170991
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:11.
Weiner MW, Alzheimer's disease Neuroimaging Initiative 2 Protocol. 2015.
Lim YY, Ellis KA, Harrington K, et al. Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Clin Exp Neuropsychol. 2012;34:345-358. doi:10.1080/13803395.2011.643227
Edgar CJ, Siemers E, Maruff P, Petersen RC, Aisen PS. Pilot evaluation of the unsupervised, at-home cogstate brief battery in ADNI-2. J Alzheimer's Dis. 2021;83:915-925. doi:10.3233/JAD-210201
Alden EC, Pudumjee SB, Lundt ES, et al. Diagnostic accuracy of the cogstate brief battery for prevalent MCI and prodromal AD (MCI A+T+) in a population-based sample. Alzheimer's Dement. 2021;17:584-594. doi:10.1002/alz.12219
Services USD of H and H. Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products. 2019.
Marson DC, Sawrie SM, Snyder S, et al. Assessing financial capacity in patients with Alzheimer disease. Arch Neurol. 2000;57:877-884.
Marson D. Investigating functional impairment in preclinical Alzheimer's disease. J Prev Alzheimer's Dis. 2016;2:4-6. doi:10.14283/jpad.2015.44.Investigating
Gerstenecker A, Triebel K, Eakin A, Martin R, Marson D. Exploring the factor structure of financial capacity in cognitively normal and impaired older adults. Clin Gerontol. 2019;41:33-41. doi:10.1080/07317115.2017.1387211.Exploring
Tolbert S, Liu Y, Hellegers C, et al. Financial management skills in aging, MCI and dementia: cross sectional relationship to 18F-florbetapir PET cortical β-amyloid deposition. J Prev Alzheimer's Dis. 2019;6:274-282.
Gonzalez C, Tommasi NS, Briggs D, et al. Financial capacity and regional cerebral tau in cognitively normal older adults, mild cognitive impairment, and Alzheimer's disease dementia. J Alzheimer's Dis. 2021;79:1133-1142. doi:10.3233/JAD-201122.Financial
Schmidt ME, Chiao P, Klein G, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET : points to consider and recommendations for controlling variability in longitudinal data. Alzheimer's Dement. 2015;11:1050-1068. doi:10.1016/j.jalz.2014.09.004
Meyer PT, Hellwig S, Amtage F, et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11 C-labeled pittsburgh compound B. J Nucl Med. 2011;52:393-400. doi:10.2967/jnumed.110.083683
Hsiao I-T, Huang C-C, Hsieh C-J, et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging. 2012;39:613-620. doi:10.1007/s00259-011-2051-2
Yoon H, Sahn B, Hyang J, et al. NeuroImage : clinical Dual-phase 18 F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer ’ s disease. NeuroImage Clin. 2021;31:102773.
Matthews DC, Strother SC, Lukic AS, Andrews RD, Wernick MN, Schmidt ME. Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier. Transl Res Clin Interv. 2022;8:1-12. doi:10.1002/trc2.12325
Chen YJ, Rosario BL, Mowrey W, et al. Relative 11 C-PiB delivery as a proxy of relative CBF: quantitative evaluation using single-session 15 O-water and 11 C-PiB PET. J Nucl Med. 2015:1199-1205. doi:10.2967/jnumed.114.152405
Devous MD. Employing early uptake data from F18- Florbetapir scans as an estimate of regional cerebral blood flow: comparison to F18-FDG. Alzheimer's Dement. 2014(Alzheimer). doi:10.1016/j.jalz.2014.05.190
Myoraku A, Klein G, Landau S, Tosun D. Regional uptakes from early-frame amyloid PET and 18F-FDG PET scans are comparable independent of disease state. Eur J Hybrid Imaging. 2022;6:2. doi:10.1186/s41824-021-00123-0
Schwarz CG, Kremers WK, Wiste HJ, et al. NeuroImage Changing the face of neuroimaging research : comparing a new MRI de-facing technique with popular alternatives. Neuroimage. 2021;231:117845. doi:10.1016/j.neuroimage.2021.117845
Ramanan VK, Nho K, Shen L, et al. FASTKD2 is associated with memory and hippocampal structure in older adults. Mol Psychiatry. 2015;20:1197-1204. doi:10.1038/mp.2014.142
Saykin AJ, Shen L, Foroud TM, et al. Alzheimer's disease neuroimaging initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimer's Dement. 2010;6:265-273. doi:10.1016/j.jalz.2010.03.013
Booij BB, Lindahl T, Wetterberg P, et al. A gene expression pattern in blood for the early detection of Alzheimer’ s disease. J Alzheimer's Dis. 2011;23:109-119. doi:10.3233/JAD-2010-101518
Lunnon K, Smith R, Hannon E, et al. Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nat Neurosci. 2014;17:1164-1170. doi:10.1038/nn.3782
Jager PL De, Srivastava G, Lunnon K, et al. Alzheimer ’ s disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Publ Gr. 2014;17:1156-1163. doi:10.1038/nn.3786
Vasanthakumar A, Davis JW, Idler K, et al. Harnessing peripheral DNA methylation differences in the Alzheimer ’ s Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease. Clin Epigenetics. 2020;12:84.
Li QS, Vasanthakumar A, Davis JW, et al. Association of peripheral blood DNA methylation level with Alzheimer ’ s disease progression. Clin Epigenetics. 2021:1-16. doi:10.1186/s13148-021-01179-2
Kim BH, Vasanthakumar A, Li QS, et al. Integrative analysis of DNA methylation and gene expression identifies genes associated with biological aging in Alzheimer's disease. Alzheimer's Dement Diagnosis, Assess Dis Monit. 2022;14:1-13. doi:10.1002/dad2.12354
Tombaugh TN, Mclntyre NJ. The mini-mental state examination. Prog Geriatr. 1992;40:922-935.
Pasternak E, Smith G. Cognitive and neuropsychological examination of the elderly. 1st ed. Elsevier B.V.; 2019. doi:10.1016/B978-0-12-804766-8.00006-6
Montgomery V, Harris K, Stabler A, Lu LH. Effects of delay duration on the WMS logical memory performance of older adults with probable Alzheimer ’ s disease, probable vascular dementia, and normal cognition. Arch Clin Neuropsychol. 2017;32:375-380. doi:10.1093/arclin/acx005
Lennon JC, Resch ZJ, Aita SL, et al. Black and White individuals differ in dementia prevalence, risk factors, and symptomatic presentation. Alzheimer's Dement. 2022:1461-1471. doi:10.1002/alz.12509
Aging NI on. Data shows racial disparities in Alzheimer's disease diagnosis between Black and White research study participants. 2021.
Aging NI on. Together we make the difference: National strategy for recruitment and participation in Alzheimer's and related dementias clinical research. 2019.
Weiner MW, Albala B, Jack Jr. CR, et al. Increasing participant diversity in AD research : plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer ’ s Disease Neuroimaging Initiative 4. Alzheimer's Dement. 2023;19:307-317. doi:10.1002/alz.12797
Poldrack RA, Gorgolewski KJ. Making big data open : data sharing in neuroimaging. Nat Neurosci. 2014;17:1510. doi:10.1038/nn.3818
Wyman BT, Harvey DJ, Crawford K, et al. Standardization of analysis sets for reporting results from ADNI MRI data. Alzheimer's Dement. 2014;9:332-337. doi:10.1016/j.jalz.2012.06.004.Standardization
Raket LL. Statistical disease progression modeling in Alzheimer disease. Front Big Data. 2020;3:1-18. doi:10.3389/fdata.2020.00024
Zettergren A, Lord J, Ashton NJ, et al. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's disease neuroimaging initiative. Alzheimer's Res Ther. 2021;13:1-10. doi:10.1186/s13195-020-00754-8
Schwarz AJ, Shcherbinin S, Slieker LJ, et al. Topographic staging of tau positron emission tomography images. Alzheimer's Dement Diagnosis, Assess Dis Monit. 2018;10:221-231. doi:10.1016/j.dadm.2018.01.006
Goudey B, Fung BJ, Schieber C, Disease A. A blood-based signature of cerebrospinal fluid A β 1 - 42 status. Sci Rep. 2019;9:4163:1-12. doi:10.1038/s41598-018-37149-7
Tosun D, Veitch D, Aisen P, et al. Detection of b -amyloid positivity in Alzheimer ’ s disease neuroimaging initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Commun. 2021;3:fcab008. doi:10.1093/braincomms/fcab008
Cullen NC, Zetterberg H, Insel PS, et al. Comparing progression biomarkers in clinical trials of early Alzheimer's disease. Ann Clin Transl Neurol. 2020;7:1661-1673. doi:10.1002/acn3.51158
Jones-Davis D, Buckholtz N. The impact of ADNI: what role do public-private partnerships have in pushing the boundaries of clinical and basic science research on Alzheimer's disease? Alzheimer's Dement. 2015;11:860-864. doi:10.1016/j.jalz.2015.05.006.The
Marek K, Jennings D, Lasch S, et al. The Parkinson progression marker initiative (PPMI). Prog Neurobiol. 2011;95:629-635. doi:10.1016/j.pneurobio.2011.09.005.The
Huie JR, Mondello S, Lindsell CJ, et al. Biomarkers for traumatic brain injury: data standards and statistical considerations. J Neurotrauma. 2021;38:2514-2529. doi:10.1089/neu.2019.6762